SEC Form 4 · accession 0001140361-16-056154
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Feb 29, 2016
Accepted (ET)
Mar 2, 2016 · 8:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 29, 2016 | F | 46,766 | $81.87 | D | 54,311 | D | |
| Common StockF1,F2 | Mar 2, 2016 | S | 4,623 | $86.1172 | D | 49,688 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed September 14, 2015.
- F2The price in column 4 is an average weighted price. The price actually received ranged from $84.23 to $87.18. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.